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Letters to the Editor8 weeks of sofosbuvir/ledipasvir is effective in DAA-naive
non-cirrhotic HCV genotype 4 infected patients (HEPNED-001 study)Although the first clinical trials with DAA’s were primarily
focused on HCV genotype 1 infections, the advent of pan-geno-
typic DAA’s give us the opportunity to study new treatment
options and even treatment shortening for genotype 4 infec-
tions.4 Indeed, LDV showed a high potency in a study that
assessed the phenotypic susceptibility of various genotype 4
subtypes6 and in the study that led to the registration of
12 weeks of SOF/LDV for genotype 4, in which 41 of the 44
(93%) patients achieved a sustained virological response
(SVR).7 Given the very comparable cure rates after 12 weeks
of SOF/LDV for genotype 1 and 4, a treatment duration of
8 weeks may be appropriate for genotype 4 as well.8 Recently,To the Editor:
In contrast to genotype 1, genotype 4 hepatitis C (HCV) infec-
tions are more often found in Central Africa and the Middle East
with the highest prevalence in Egypt.1 As the initial budget
impact of HCV treatment with direct-acting antivirals (DAAs)
can be substantial for countries with a high HCV prevalence,2
shortening treatment duration could help in reaching the World
Health Organization’s HCV elimination goals3 by lowering costs
and expanding access.4 The most recent EASL guideline suggests
8 weeks of therapy with sofosbuvir/ledipasvir (SOF/LDV) as an
option for treatment-naive non-cirrhotic patients with chronic
HCV of the genotypes 1a and 1b.5554 Journal of Hepatology 2019 vol. 70 j 548–577
this approach was studied in Egyptian patients and a cure rate
of 95% (41/43) was observed in the 43 patients.9 However, these
patients were HIV-negative and because genotype 4a is the
most prevalent HCV subtype in Egypt, these results cannot be
translated to other genotype 4 subtypes.1
We evaluated the effectiveness of 8 weeks SOF/LDV for geno-
type 4 HCV-infected DAA-naive HIV-positive and -negative
patients without cirrhosis in a single arm prospective open label
study in 10 centers in the Netherlands and Belgium and found a
high effectiveness these patients.
The primary outcome was SVR in the on-treatment (OT)
study population, defined as an HCV RNA below the limit of
detection 12 weeks after the end of therapy in all patients that
had completed the 8-week treatment course of therapy and
had an HCV RNA measurement ≥12 weeks after the end of
therapy. Eligible participants were HIV-negative or HIV-positive
adults chronically infected with HCV genotype 4 with a
screening HCV RNA load <10 million IU/ml. Patients with a
history of DAA treatment failure for the current episode of
HCV, a liver biopsy with a METAVIR score above F3 or a liver
stiffness measurement (FibroScan) ≥12.5 kPa were excluded.
Because HCV reinfections are frequently observed in
HIV-infected men who have sex with men (MSM), it was
predefined in the protocol that HCV reinfections diagnosed
by a genotype switch or by phylogenetic analysis10 will not
be counted as treatment failure.
From January 2016 until June 2017, 63 patients were
screened for eligibility of whom 44 were enrolled. Four
patients never started therapy and 30 HIV-positive and 10
HIV-negative patients started treatment (Fig. S1). All patients
completed the 8 weeks of therapy, but 1 HIV-negative patient
was lost to follow-up before SVR could be evaluated (last HCV
viral load <15 IU/ml). In the on-treatment population, 33 of
the 39 patients were HCV RNA negative 12 weeks after
therapy and 6 were HCV RNA positive. However, 4 of them
had a proven reinfection (Fig. S2). These 4 patients were all
MSM and had ongoing unprotected sex, underlining the
urgent need for effective interventions to decrease the risk
of reinfection in this subpopulation. In total, 37 of 39 patients
(95%; 95% CI 83–99%) of the on-treatment population were
successfully treated for the HCV that was present at baseline.
Stratified to HIV-status, 28 of the 30 HIV-positive patients
(93%; 95% CI 80–99%) and 9 of the 9 HIV-negative patients
(100%) reached SVR12 (p = 1.0) (Table 1). In the 2 treatment
failures, the baseline HCV viral loads were 9.8E5 and
8.7E6 IU/ml. The subtype was 4c in one patient, but in the other








Age (yr)a, mean ± SD 51 ( ± 9.9) 51 ( ± 10.4) 51 ( ± 8.7) 0.971
Maleb, % (n) 85% (34/40) 86,7% (24/30) 80% (8/10) 1.000
Caucasianb, % (n) 80% (32/40) 76,7% (23/30) 90% (9/10) 0.653
Transmission mode HCVb 0.068
MSM, % (n) 52.5% (21/40) 63.3% (19/30) 20% (2/10)
IVDU, % (n) 12.5% (5/40) 10% (3/30) 20% (2/10)
Other, % (n) 7.5% (3/40) 6.7% (2/30) 10% (1/10)
Missing, % (n) 27.5% (11/40) 20% (6/30) 50% (5/10)
Previous treatmentb, % (n) 0.011
Naive (no treatment) 80% (30/40) 83,3% (25/30) 70% (7/10)
PegIFN ± ribavirin 20% (8/40) 16.7% (5/30) 30% (3/10)
Baseline viral load (IU/ml)c, median (IQR) 1.05 E6(3.36 E5–3.64 E6) 1.21 E6(3.97 E5–3.37 E6) 6.9 E5(1.75 E5–2.00 E6) 0.235
Time since diagnosis of HCV infection (yr)c, median (IQR) 4.2 (2.1–9.8) 4.4 (2.8–10.1) 4.4 (4.0–4.9) 0.331
HCV subtypeb, % (n) 0.304
4a 15% (6/40) 10% (3/30) 30% (3/10)
4c 2.5% (1/40) 3.3% (1/30) 0%
4d 37.5% (15/40) 40% (12/30) 30% (3/10)
4t 2.5% (1/40) 0% 10% (1/10)
Unknown 42.5% (17/40) 46.6% (14/30) 30% (3/10)
Liver stiffness measurement (FibroScan)
pKac, median (IQR) 5.6 (4.5–7.6) 5.3 (4.2–6.8) 8.8 (6.5–10.8) 0.004
F3 (>9.5 kPa)b, % (n) 15% (6/40) 3.3% (1/30) 50% (5/10) 0.002
CD4 cell count (cells/ll), mean ± SD
Nadir n.a. 397.9 ± 53.9 n.a.
At start of HCV therapy n.a. 807.0 ± 69.0 n.a.
On Cart, % (n) n.a. 100% (30/30) n.a.
HIV viral load <40 copies/ml at start of HCV therapy, % (n) n.a. 97% (29/30) n.a.
Outcomes in on-treatment populationd
Effectiveness OT population
%, n 95% (37/39) 93% (28/30) 100% (9/9)
95% exact CIe 83–99% 80–99% –
HCV RNA negative 12 weeks after therapy 33 24 9
HCV RNA positive 12 weeks after therapy
Reinfection (genotype switch) 1 1 –
Reinfection (phylogenetically distinct genotype 4 virus) 3 3 –
Relapse 2 2 –
cART, combined antiretroviral therapy; HCV, hepatitis C virus; IVDU, intra-venous drug use; MSM, men who have sex with men; n.a., not applicable; OT, on-treatment.
a T-test. b Fisher’s exact test. c 2-sided Mann-Whitney U test. d Reinfections are not considered treatment failure. e 2-sided Clopper Pearsons confidence interval.
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patient the subtype was not typable. No resistance associated
mutations in NS5a or NS5b were detected at the time of HCV
relapse.
As a result of the rapid treatment uptake of DAAs in HIV-
infected MSM in the Netherlands and Belgium,11 the inclusion
of additional patients was not possible because after the screen-
ing of 63 and the treatment of 40 genotype 4 patients, no
eligible patients were left in any of the participating centers.
Therefore, we did not reach the intended sample size of 41
patients as stated in the protocol of our study (as described
supplementary information). However, although relatively
small, our sample size was comparable to the number of
patients included in phase III trials of SOF/LDV that led to the
registration of 12 weeks SOF/LDV therapy for HCV genotype 4.5
Our study showed that 8 weeks of SOF/LDV could be an
effective therapy for non-cirrhotic HCV genotype 4 infected
patients with an HCV RNA load <10 million IU/ml and is the first
to evaluate the efficacy of 8 weeks of SOF/LDV in a substantial
number of HIV-coinfected patients. Our results further
strengthen the observation made among Egyptian mono-
infected patients.9 Therefore, 8 weeks of SOF/LDV could be con-
sidered a treatment option in DAA-naïve genotype 4 patients
without cirrhosis, thereby expanding access to therapy to a lar-
ger number of patients.
The extended version of the methods and ethics statement
(S1), the flow diagram of the study (S2) and the phylogenetic
analysis (S3) can be found in the online supplements.
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Over-gap PCR amplification to identify presence of
replication-competent HBV DNA from integrated HBV DNA:
An updated occult HBV infection definition
To the Editor:
With great interest, we read the manuscript ‘‘Quantitation of
HBV cccDNA in anti-HBc-positive liver donors by droplet digital
PCR: a new tool to detect occult infection” by Caviglia et al. pub-
lished in Journal of Hepatology.1 Using a highly sensitive in-house
droplet digital PCR assay (ddPCR) method, the authors indicated
that intrahepatic HBV covalently closed circular (cccDNA) was
detectable in about half (52%, 27/52) of the defined cases of
occult HBV infection (OBI). We wonder whether the pretreat-
ment with plasmid-safe ATP dependent DNase (PSAD) plus dou-
ble-over-gap cccDNA ‘specific’ primers spanning the HBV
relaxed circular DNA (rcDNA) gap region used in this paper could
totally eliminate the interference of rcDNA, though this method
had been widely used in the detection of cccDNA.2 Here we eval-
uated the capacity of the above approach to discriminate
between the cccDNA, the rcDNA and the integrated double
strand linear HBV DNA (dslDNA). In addition, several sets of
mono-over-gap rcDNA primers (Table S1) were also tested,
which theoretically can amplify both rcDNA and cccDNA.3
First, to exclude the likely cccDNA contaminant leaked from
cells, the supernatant of HepAD382 and serum specimens from
patients with HBV infection4 were treated with DNase I prior to
viral DNA extraction and PCR amplification. The elimination
efficiency was confirmed by the failed amplification of plasmid
DNA containing 1.2xHBV genome (Fig. 1A). In contrast, the HBV
rcDNA in Dane particles could still be detected by using the sup-
posed cccDNA ‘specific’ primers, which provided a similar result
compared to rcDNA primers. Moreover, the gradual increase of
HBV DNA level was observed in parallel with the increased
amount of rcDNA, when either the supposed cccDNA primers
or the rcDNA primers were used (Fig. 1B). As previously
reported,5 the rcDNA could not be eliminated completely pre-
treatment by PSAD and this was further confirmed by T5 Exonu-
clease and Exonuclease III, respectively (Fig. 1C, D). Hence, PSAD
digestion plus double-over-gap PCR may not guarantee the dis-
crimination of cccDNA from rcDNA.
The term ‘occult hepatitis B virus infection’ has been intro-
duced to describe a status characterized as an absence of serum
HBV surface antigen and presence of replication-competent
HBV DNA in the liver.6–8 Since cccDNA is the resource for viral
replication and the reason for HBV infection persistence, the
presence of cccDNA for OBI is indispensable. The integrated
HBV DNA fragments, on the other hand, have an incomplete
viral genome which lost the capacity to serve as the template
for HBV replication. Therefore, it is reasonable to postulate that
the detection of cccDNA, but not the presence of integrated HBV
DNA fragment, is essential for true OBI. Moreover, it may not be
necessary to distinguish cccDNA from rcDNA for the definition
of OBI because the rcDNA originates solely from the transcrip-
tionally active cccDNA.9
Integration of HBV DNA fragments is a common event during
HBV infection. Our previous study revealed that the breakpoints
of the integrated HBV DNA fragments were mainly found within
the DR1 and DR2 regions (Fig. 1E).4 This is in accordance with
the suggestion that HBV dslDNA is the preferred form for viral
DNA integration into the host genome.10 To test if the integrated
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